This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
Trump Plans Steady Economic Reboot: 5 Coronavirus-Proof Bets
by Aniruddha Ganguly
Here we discuss five stocks poised to gain maximum benefits from the staggered reopening of U.S. economy, per the latest guidelines.
Coronavirus Puts Digital Health in Focus: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are focusing on digital health to fight against coronavirus.
Here's Why Momentum Investors Will Love Masimo (MASI)
by Zacks Equity Research
Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
ResMed (RMD) Grows on Stellar Mask Sales, SaaS Capabilities
by Zacks Equity Research
Within SaaS, ResMed (RMD) shows strong momentum in the Brightree service portfolio.
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
by Zacks Equity Research
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
5 Stocks With Recent Price Strength Amid Coronavirus Logjam
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Low-Risk Stocks to Buy for Epic Price Swings Since 1929
by Tirthankar Chakraborty
The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.
Nevro (NVRO) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Here's Why Investors Should Buy Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) sees a slew of developments lately.
Masimo & University Hospitals Unite for Patient Monitoring
by Zacks Equity Research
Masimo (MASI) sees a plethora of developments lately.
Why Is Masimo (MASI) Down 9.6% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo's Latest Buyout to Boost Respiratory Product Spectrum
by Zacks Equity Research
Masimo (MASI) expects the transaction to be neutral to 2020 earnings.
4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis
by Debanjana Dey
Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.
Has Masimo (MASI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Masimo Inks Deal With Imprivata, Improves Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.
Masimo (MASI) Gets FDA Nod for RRp Monitoring Technology
by Zacks Equity Research
The FDA clearance of this monitoring system is expected to strengthen Masimo's (MASI) portfolio of pulse oximetry technologies.
Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive
by Zacks Equity Research
Masimo (MASI) sees expansion in gross and operating margin in Q4.
COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus
by Sriparna Ghosal
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.